Stock Analysis:Nevro Corp (NYSE:NVRO) Price Target Upgraded
In analysts note shared with investors by Leerink Swann on Tuesday morning, Nevro Corp (NYSE:NVRO) had its target PPS increased to $75.00. The firm now has a solid “Outperform” rating on shares.
From a total of 6 analysts covering Nevro Corp (NYSE:NVRO) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $78 while the lowest target price is $67. The mean of all analyst targets is $71 with a 11.11% above today’s ($63) stock price. Nevro Corp was the topic of 3 analyst reports since August 13, 2015 according to the firm StockzIntelligence Inc. BMO Capital Markets initiated shares on September 25 with “Outperform” rating.
The stock increased 1.38% or $0.86 during the last trading session, striking $63. Approximately shares of stock traded hands. Nevro Corp (NYSE:NVRO) has risen 37.70% since May 6, 2015 and is uptrending. It has outperformed by 38.50% the S&P500.
Nevro Corp. is a medical device company. The company has a market cap of $1.74 billion. The Firm makes and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. It currently has negative earnings. The Firm developed and commercialized a neuromodulation platform for the treatment of chronic pain.
According to Zacks Investment Research, “Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California.” Get a free copy of the Zacks research report on Nevro Corp (NVRO).